Systematic Review of Light-Based Treatments for Hidradenitis Suppurativa

Cazaña, T. Gracia; Díaz, L.V. Berdel; Sánchez, Juan Ignacio Martín; Nasarre, Ignacio Querol; Gilaberte, Yolanda

doi:10.1016/j.adengl.2019.04.019

Cited by 3 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Light sources also vary, including red light (635 nm), blue light, Intense Pulsed Light (630 nm), and laser diode (400 nm). 106 Response rates are not comparable between studies, but intralesional PDT seems to determine better outcomes and the axillary region has better response rates. 112…”

Section: Treatmentmentioning

confidence: 98%

“…Laser and photodynamic therapy (PDT) have been used alone and in combination with other therapies with variable results. 106 Comparison between treatment modalities is challenging because there are no standardized treatment protocols using these devices and settings vary between machines. Larger randomized controlled trials are needed to elucidate their role and determine the optimal treatment settings.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

New perspectives on the treatment of hidradenitis suppurativa

Amat-Samaranch

Agut-Busquet

Vilarrasa

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the presence of painful nodules, abscesses, chronically draining fistulas, and scarring in apocrine gland-bearing areas of the body. The exact pathogenesis of HS is not yet well understood, but there is a consensus in considering HS a multifactorial disease with a genetic predisposition, an inflammatory dysregulation, and an influence of environmental modifying factors. Therapeutic approach of HS is challenging due to the wide clinical manifestations of the disease and the complex pathogenesis. This review describes evidence for effectiveness of current and emerging HS therapies. Topical therapy, systemic treatments, biological agents, surgery, and light therapy have been used for HS with variable results. Adalimumab is the only US Food and Drug Administration (FDA) approved biologic agent for moderate-to-severe HS, but new therapeutic options are being studied, targeting different specific cytokines involved in HS pathogenesis. Comparing treatment outcomes between therapies is difficult due to the lack of randomized controlled trials. Treatment strategy should be selected in concordance to disease severity and requires combination of treatments in most cases.

show abstract

Section: Treatmentmentioning

confidence: 98%

Section: Treatmentmentioning

confidence: 99%

New perspectives on the treatment of hidradenitis suppurativa

Amat-Samaranch

Agut-Busquet

Vilarrasa

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Available therapies could be divided into medical and surgical treatments 1 . Management often includes combined treatment, such as antibiotics and/or immune system modulators for global control of the disease, and lesion‐directed treatments such as corticosteroid infiltration, local surgery, or intralesional photodynamic therapy (iPDT), which has produced mixed results due to the use of different photodynamic agents and light sources, and the lack of randomized controlled trials 9 …”

Section: Introductionmentioning

confidence: 99%

“…In order to better reach the target tissue, a technique based on a laser diode attached to an optical cable has recently been developed. Efficacy of PDT in HS has been evaluated in prospective and retrospective case series and single‐blind RCTs 9,15 . Our objective is to add new evidence to the use of intralesional methylene blue PDT.…”

Section: Introductionmentioning

confidence: 99%

Ultrasound‐guided photodynamic therapy with intralesional methylene blue and a 635 nm light‐emitting diode lamp in hidradenitis suppurativa: A retrospective study of 41 patients

Gamissans

Riera-Martí

Romaní

et al. 2021

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Background Photodynamic therapy for hidradenitis suppurativa (HS) is a therapeutic alternative with a good safety profile, but its effectiveness has yet to be demonstrated. Objectives To demonstrate the effectiveness of PDT with intralesional methylene blue in HS lesions. Methods A retrospective cross‐sectional study was performed. Forty‐one patients were treated with intralesional methylene blue and a diode lamp. Follow‐up was carried out at 1 and 6 months after therapy. Efficacy was determined by the diameter reduction of the lesion measured by high‐frequency ultrasound. Results A reduction of ≥75% in the maximum diameter was recorded in 58.5% of the lesions, while 22% showed a reduction between 50% and 75%, and 19.5% showed a reduction of <50%. Recurrence rate was 12.5%. The lesions treated in patients with typical forms of HS (Canoui‐Poitrine phenotype I) had a better therapeutic response. No statistically significant differences were found in terms of lesion location or concomitant treatment. Conclusion This therapy may potentially be a cost‐effective and well‐tolerated local therapy for Hurley I‐II patients with superficial abscesses and fistulas.

show abstract

Minimally invasive management of Hidradenitis suppurativa using a 1470nm diode laser. A step-by-step description of our technique.

Brown,

Kumassah,

Brown

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The management of hidradenitis suppurativa (HS) requires a multidisciplinary approach to ensure sustainable treatment results, especially in the advanced stages. Traditionally, deroofing and wide excision represented commonly employed surgical techniques. Due to the recurrent nature of HS, tissue preservation should be a relevant aspect of the surgical management. The aim of this manuscript is to demonstrate the use of a diode laser for the management of different stages of HS, paying attention on tissue preservation. Methods This is a technical manuscript demonstrating our technique for laser–assisted management of HS. A diode laser with a wavelength of 1470nm was used for this indication. The depth of the sinus/tract dictates the amount of energy required. Our preference is to use 8 Watts for deep lesions and 5 Watts for shallow lesions. Results: The following 7 critical steps are important to achieve an optimal result with this technique: Drain all collections, minimalize tissue damage, protect healthy skin, control risk factors, adopt a multidisciplinary approach, follow-up closely, and be patient. Conclusion: Laser-based management of hidradenitis suppurativa is a promising surgical option in the multidisciplinary treatment of this difficult pathology. The minimally invasive nature of laser surgery, especially tissue preservation, is a strong argument for the role of this technique in the management of this chronic, recurrent condition.

show abstract

Systematic Review of Light-Based Treatments for Hidradenitis Suppurativa

Cited by 3 publications

References 50 publications

New perspectives on the treatment of hidradenitis suppurativa

New perspectives on the treatment of hidradenitis suppurativa

Ultrasound‐guided photodynamic therapy with intralesional methylene blue and a 635 nm light‐emitting diode lamp in hidradenitis suppurativa: A retrospective study of 41 patients

Minimally invasive management of Hidradenitis suppurativa using a 1470nm diode laser. A step-by-step description of our technique.

Contact Info

Product

Resources

About